Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Depends what the term sheet competition says.
Only other competitor for preventing OM is a 35 day IV treatment and much more costly.
IPIX is an oral rinse for OM prevention.
An interested party would want the much less expensive, patient friendly drug for OM prevention.
They know that doctor's would prescribe this first if it's equivalent to the 35 day IV treatment.
And insurance companies would favor it over everything else.
Keep OM drug costs down..ie higher company profits, insurance companies more profitable, and treatments done at home.
A win for all parties involved with the drug.
oh ic, I didn't look back at the PR, thought it was in vivo
https://www.verywellhealth.com/what-does-in-vivo-and-in-vitro-mean-2249118
thanks
I was expecting news next week.
Don't care what profit takers did today before news.
BDD confirmed the successful colon targeting of Brilacidin in the animal model back in September thru an IPIX PR.
So you were expecting a leak, before the topline results.
Maybe some folks took some profit off the table before results.
We are talking about a clinical trial here.
For right now, BDD controls when the info will be released to IPIX.
What is your expected deadline for these results...do you have one or many possibilities in mind?
You mean BDD and IPIX are going to leak information...if it happens those folks lose their jobs.
It was said topline results shortly when last dose was completed, maybe it's up to BDD Pharma to get things together, how long it takes, my guess next week sometime.
Today is the start of last day for denoting any adverse events.
Give me your high price where someone knows?
what if was trading at .069, .070 a bit higher, does this also mean someone knows?
What would you like to be said.
Topline results include adverse events, today being
start of 14th day to capture the last analyzed day
of adverse events.
Topline data should be known next week.
The adverse event timeframe was a capture period of 14 days.
Last dosing was 2 Fridays ago ~ 14 days implies after today.
https://clinicaltrials.gov/ct2/show/NCT04240223?term=brilacidin&draw=2&rank=3
A sustained response on the target would be significant based on the dosage percentage that hit the target (drug absorption) and its effect on the disease. Brilacidin seems to do a great job at all dose levels for the UP/UPS enema, while the pill ingredients may have good attachment features (stickiness) to the colon after proper placement on the target. Just don't know what chemical ingredients and reactions are in the BDD pill besides Brilacidin.
Novartis seems to like Oralogik...license purchased.
Both big markets, UC and Crohns, so something non-steroid, non-biologic that works well would capture some reves from those markets which are quite large.
Oralogik is supposedly functioning independent of agitation in the colon.
Particles embedded in the drug can be free flowing,
check out these results on colonic delivery (2011 Article).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549889/
The results are not delayed and not been given.
Only BDD and IPIX know. Nothing is leaked.
And they cannot trade on inside information.
Adverse events gathering probably finishing this Friday.
Why you insist outcome without knowing??
Topline results most likely include adverse events.
This trial link shows adverse event timeframe of 14 days.
https://clinicaltrials.gov/ct2/show/NCT04240223?term=brilacidin&draw=2&rank=3
14 days out has not been reached yet - probably upcoming Monday.
Then everything is known and just a matter of when post Monday
the topline data is released.
Respect the process.
Probably not, MFO doesn't want to counteract a potential rise in price if topline results are very good to excellent.
The 2nd dosing was announced in this dose escalation PR and scheduled for Jan 21.
http://www.ipharminc.com/press-release/2020/1/17/innovation-pharmaceuticals-announces-dose-escalation
The First Right To Negotiate has not been granted to any BP yet for B-UC or B-Crohns.
Maybe a BP substantial amount (well more than needed for P2A), winning bid for funding a P2A would allow that BP the First Right To Negotiate on B-UC.
I agree B is out there in several parts.
I thought Dr B had retired Pfizer connections in Michigan that he was consulting with for the oral K.
Believe I read it thru once or twice thru this site last year.
I'm not sure they would go this route thru only medics.
Why not get oncology Dr suggestions from Dana Farber (in Boston Mass) where Kevetrin Phase 1 took place. Or Massachusetts General Hospital.
Or advice from Dr B, who spent some eventful time at Pfizer and Novartis.
They have Dr. Frances Farraye (supposedly top notch) as a GI consultant.
So your probably right...oncology for BOM and K.
I'm not sure they would go this route thru only medics.
Why not get oncology Dr suggestions from Dana Farber (in Boston Mass) where Kevetrin Phase 1 took place. Or Massachusetts General Hospital.
Or advice from Dr B, who spent some eventful time at Pfizer and Novartis.
The ad says 2019, should be 2020
It says see (via link) who OnlyMedics has hired for this role on the initial page, but I can't determine who it is.
How are you sussing IPIX out of the job details?
Do you have a paid professional account to this site?
Huh? Don't reckon I see IPIX...did you accidently send the wrong link?
May very well be IPIX took guidance from potential partners on what
delivery technology they would like to see tested before a collaboration agreement.
Did several potential partners bring up the use of BDD Oralogik?
Novartis,....who else...remains a mystery.
Novartis signed an Oralogik license for an undisclosed compound.
Did they test Oralogik with the undisclosed compound in
Novartis labs about 9 months in advance before IPIX signed with BDD.
Kind of giving the thumbs up.
The phase 2A would be Proof of Concept.
My understanding from Investor Meeting was a 2A.
Theravance Biopharama did a POC themselves and
hooked Janssen.
How many needed at what cost?
30-40 patients ?? Cost per patient??
Need funding for the trial...need a BOM deal.
Or sell Kevetrin.
Basil, thinking they should sell the company.
As much as I like Brilacidin, someone big needs to takeover running numerous trials in parallel for those indications having big markets and get some drugs to market.
Did Ke invest JP Morgan money supporting Ruby after a JP Morgan healthcare conference meetup with Ruby last year?
HI,
Mako felt the assets were worth nothing, by saying the stock was worth nothing.
In the end, their assets were worth something to a big pharmaceutical company. Scooped them up.
Yes, remember that time too.
I have to agree. Locust Walk has all the business models to analyze projections and has a far reach to many companies worldwide.
LE doesn't have the time nor years of experience they have to move things along and cut a fair deal.
AS to me comes off as cheap, I'd rather see IPIX avoid them in any other negotiations.
A buyout would do that, there are bigger players out there.
Well we don't know if AS was the only one bidding on BUP at the time.
B-UP I believe is only 20% of ulcerative colitis.
I understand your distraught.
Was thinking 3-4 million upfront. And better royalties, milestones.
B-UP results did show promise and hope that shows
in value higher up the gi tract for an oral pill
(non-biologic, non-steroid), where most of the
revenues will be made for IBD.